1.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0888, NCT01198028
|
|
2.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: ENT0033, SU-08222011-8290, 22329, NCI-2011-03271, NCT01437449
|
|
3.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 514-2012, 00086505, NCT01764607
|
|
4.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Onconova 09-09, COMIRB 13-0116, NCT01807546
|
|
5.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: SKIN0016, NCI-2013-00710, 26699, NCT01823679
|
|
6.
|
Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UFPTI 0606-SK01, NCT00797043
|
|
7.
|
Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 50 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTPR-0002, NCT01016899
|
|
8.
|
Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PRO10030462, NCT01252329
|
|
9.
|
Phase: No phase specified Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: IRB00012329, NCT01526486
|
|
10.
|
Phase: No phase specified Type: Treatment Status: Active Age: 35 to 90 Sponsor: Pharmaceutical / Industry Protocol IDs: MT-DMG-1, NCT01536444
|